Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Fluorouracil (5-FU)
DRUG: Capecitabine
BIOLOGICAL: Durvalumab
DRUG: Oxaliplatin
BIOLOGICAL: Trastuzumab
DRUG: Trastuzumab deruxtecan
DRUG: Cisplatin
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Volrustomig
BIOLOGICAL: Rilvegostomig

Sponsor

AstraZeneca

Collaborators

[object Object]